ABL501
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ABL501, covering 2024-07-31 to 2024-07-31. Get the full timeline:
Most recent: Clinical Trial Update: Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors [Phase 1]